Nifty
Sensex
:
:
11419.25
38337.01
-177.65 (-1.53%)
-560.45 (-1.44%)

Pharmaceuticals & Drugs

Rating :
56/99  (View)

BSE: 532296 | NSE: GLENMARK

432.85
-8.00 (-1.81%)
19-Jul-2019 | 3:55PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  440.80
  •  446.80
  •  431.00
  •  440.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  719816
  •  3115.72
  •  711.90
  •  423.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 12,433.74
  • 13.44
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 15,625.40
  • 0.46%
  • 2.22

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.58%
  • 3.12%
  • 9.35%
  • FII
  • DII
  • Others
  • 2.62%
  • 4.88%
  • 33.45%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.84
  • 8.83
  • 6.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.51
  • 8.17
  • 2.37

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.41
  • 8.19
  • 2.65

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.22
  • 29.97
  • 19.86

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.30
  • 5.75
  • 4.11

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.29
  • 15.52
  • 12.61

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
2,563.47
2,279.82
12.44%
2,555.05
2,203.66
15.95%
2,581.33
2,256.59
14.39%
2,165.62
2,363.00
-8.35%
Expenses
2,199.34
1,952.98
12.61%
2,120.37
1,880.97
12.73%
2,141.23
1,868.19
14.62%
1,818.73
1,785.55
1.86%
EBITDA
364.13
326.83
11.41%
434.68
322.69
34.71%
440.11
388.40
13.31%
346.88
577.45
-39.93%
EBIDTM
14.20%
14.34%
17.01%
14.64%
17.05%
17.21%
16.02%
24.44%
Other Income
39.06
69.55
-43.84%
-109.02
-23.16
-
139.88
29.73
370.50%
138.22
15.29
803.99%
Interest
81.91
74.39
10.11%
88.53
70.47
25.63%
85.13
69.84
21.89%
79.01
70.86
11.50%
Depreciation
80.97
73.53
10.12%
83.10
75.38
10.24%
82.45
75.23
9.60%
79.38
77.73
2.12%
PBT
240.31
248.47
-3.28%
154.03
153.67
0.23%
579.59
273.05
112.27%
326.70
444.14
-26.44%
Tax
78.65
96.84
-18.78%
37.69
48.93
-22.97%
165.59
58.93
180.99%
93.71
110.76
-15.39%
PAT
161.66
151.63
6.61%
116.34
104.74
11.08%
414.00
214.12
93.35%
232.99
333.38
-30.11%
PATM
6.31%
6.65%
4.55%
4.75%
16.04%
9.49%
10.76%
14.11%
EPS
5.73
5.37
6.70%
4.12
3.71
11.05%
14.67
7.59
93.28%
8.26
11.81
-30.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
2,480.46
2,086.48
Net Sales Growth
8.38%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
18.89%
18.88%
 
Cost Of Goods Sold
3,362.34
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
784.28
658.07
Gross Profit
6,503.13
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
1,696.18
1,428.41
GP Margin
65.92%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
68.38%
68.46%
Total Expenditure
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
1,860.89
1,631.50
Power & Fuel Cost
-
137.47
127.02
120.47
109.11
93.50
80.13
0.00
0.00
31.86
25.55
% Of Sales
-
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
1.28%
1.22%
Employee Cost
-
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
289.95
272.34
% Of Sales
-
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
11.69%
13.05%
Manufacturing Exp.
-
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
40.76
142.80
156.13
% Of Sales
-
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
5.76%
7.48%
General & Admin Exp.
-
805.17
1,022.89
491.20
253.29
859.67
678.94
1,331.99
854.82
268.51
258.24
% Of Sales
-
8.87%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
10.83%
12.38%
Selling & Distn. Exp.
-
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
310.32
254.38
% Of Sales
-
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
12.51%
12.19%
Miscellaneous Exp.
-
35.66
88.52
38.82
38.48
228.40
33.61
0.00
0.00
33.15
254.38
% Of Sales
-
0.39%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
1.34%
0.33%
EBITDA
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
619.57
454.98
EBITDA Margin
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
24.98%
21.81%
Other Income
208.14
91.40
37.37
20.00
6.88
11.48
10.75
18.17
144.41
50.45
179.26
Interest
334.58
285.57
237.32
178.88
190.15
188.59
160.01
146.57
160.46
165.50
145.72
Depreciation
325.90
301.88
264.37
234.28
300.41
216.79
127.01
97.88
94.68
120.61
102.68
PBT
1,300.63
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
383.90
385.84
Tax
375.64
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
52.87
75.41
Tax Rate
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
13.77%
28.04%
PAT
924.99
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
324.47
191.66
PAT before Minority Interest
924.97
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
331.03
193.47
Minority Interest
-0.02
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
-6.56
-1.81
PAT Margin
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
13.08%
9.19%
PAT Growth
15.07%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
39.67%
69.29%
 
Unadjusted EPS
32.78
28.49
39.29
26.47
7.72
20.01
22.91
17.03
16.78
12.40
7.70

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
2,355.23
1,598.16
Share Capital
28.22
28.22
28.22
27.13
27.12
27.09
27.05
27.03
26.98
25.05
Total Reserves
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
2,328.25
1,573.10
Non-Current Liabilities
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
1,940.41
2,151.27
Secured Loans
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
241.41
382.65
Unsecured Loans
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
1,627.98
1,711.69
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
14.58
6.90
0.00
0.00
Current Liabilities
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
518.62
456.33
Trade Payables
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
379.27
343.48
Other Current Liabilities
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
119.38
96.41
Short Term Borrowings
295.04
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
0.00
0.00
Short Term Provisions
432.46
262.95
134.03
216.78
259.95
33.22
10.63
11.62
19.97
16.44
Total Liabilities
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
4,827.27
4,208.92
Net Block
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
1,787.31
1,566.24
Gross Block
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
2,175.54
1,838.58
Accumulated Depreciation
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
388.23
272.33
Non Current Assets
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
2,406.20
2,129.78
Capital Work in Progress
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
145.70
600.77
545.41
Non Current Investment
14.66
15.69
17.20
17.12
0.00
0.00
0.00
0.00
18.12
18.12
Long Term Loans & Adv.
119.78
98.94
69.99
468.16
33.39
36.52
0.00
0.00
0.00
0.00
Other Non Current Assets
0.56
0.13
0.16
0.27
20.33
22.00
33.23
30.92
0.00
0.00
Current Assets
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
2,421.07
2,079.14
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
708.46
630.23
Sundry Debtors
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
1,078.28
955.34
Cash & Bank
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
195.83
107.02
71.48
Other Current Assets
1,391.61
683.39
391.88
31.44
872.81
635.91
593.95
465.11
527.31
422.09
Short Term Loans & Adv.
580.83
590.22
594.89
742.94
768.44
540.03
518.90
322.39
527.31
422.09
Net Current Assets
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
1,902.45
1,622.81
Total Assets
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01
4,827.27
4,208.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
930.58
352.40
15.91
PBT
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
383.90
268.88
Adjustment
571.28
726.56
391.03
522.76
709.78
342.45
484.05
189.65
265.26
274.15
Changes in Working Capital
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
-209.36
-387.66
Cash after chg. in Working capital
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
439.80
155.37
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
-87.40
-139.46
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
-386.91
-950.16
Net Fixed Assets
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
-52.58
406.38
Net Investments
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
-755.29
-40.93
Others
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
420.96
-1,315.61
Cash from Financing Activity
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
70.05
849.23
Net Cash Inflow / Outflow
166.21
488.24
163.27
140.86
387.61
379.11
165.21
127.70
35.54
-85.02
Opening Cash & Equivalents
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
103.58
71.48
156.51
Closing Cash & Equivalent
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
107.02
71.48

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
182.62
159.16
128.59
65.74
109.99
102.01
88.77
75.38
87.28
63.79
ROA
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
7.33%
5.42%
ROE
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
16.75%
12.42%
ROCE
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
13.88%
13.37%
Fixed Asset Turnover
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
1.25
1.43
Receivable days
94.95
97.29
119.39
125.97
115.37
104.99
107.78
136.71
148.42
151.98
Inventory Days
83.59
73.65
67.68
59.42
53.99
59.39
72.38
93.78
97.70
88.92
Payable days
96.28
101.59
117.03
95.22
83.15
68.48
108.47
106.73
68.48
62.10
Cash Conversion Cycle
82.26
69.35
70.04
90.17
86.21
95.91
71.69
123.76
177.63
178.80
Total Debt/Equity
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
0.79
1.31
Interest Cover
4.92
7.28
6.84
3.86
4.70
5.62
4.33
4.00
3.32
2.85

News Update


  • Glenmark Pharma signs licensing agreement with Torrent Pharma
    11th Jul 2019, 09:13 AM

    The company will receive an upfront payment, license fees and royalties for the non-exclusive sub-license rights from Torrent

    Read More
  • Glenmark’s arm receives USFDA’s final approval for Ranolazine Extended-Release Tablets
    9th Jul 2019, 09:10 AM

    Ranexa Extended Release Tablets, 500 mg and 1,000 mg market achieved annual sales of approximately $929.0 million

    Read More
  • Glenmark Pharma's arm receives USFDA’s approval for Ezetimibe and Simvastatin Tablets
    28th Jun 2019, 09:19 AM

    The Vytorin Tablets market achieved annual sales of approximately $92.4 million

    Read More
  • Glenmark Pharma receives complete response letter from USFDA for Ryaltris
    24th Jun 2019, 14:36 PM

    The CRL does not specify any deficiencies with the clinical data supporting the New Drug Application for Ryaltris

    Read More
  • Glenmark Pharma’s arm signs partnership agreement with Novartis Biosciences
    24th Jun 2019, 09:08 AM

    The products involved in the agreement are Seebri, Onbrize and Ultibro

    Read More
  • Glenmark Pharmaceuticals’ arm receives tentative ANDA approval for Clindamycin Phosphate Foam
    20th Jun 2019, 09:15 AM

    The company continues to identify and explore external development partnerships

    Read More
  • Glenmark to raise funds up to $200 million
    30th May 2019, 14:32 PM

    The Board of Directors of the company at its meeting held on May 29, 2019, approved the same

    Read More
  • Glenmark Pharma reports 7% rise in Q4 consolidated net profit
    30th May 2019, 10:10 AM

    The company has reported a standalone net profit of Rs 281.29 crore for the quarter ended March 31, 2019

    Read More
  • Glenmark Pharma - Quarterly Results
    29th May 2019, 21:29 PM

    Read More
  • Glenmark Pharmaceuticals to raise funds through issue of debt securities
    27th May 2019, 12:13 PM

    Proceeds from these debt securities issuance will be used mainly to refinance existing debt

    Read More
  • Glenmark gets final USFDA’s nod for Aspirin and Extended-Release Dipyridamole Capsules
    27th May 2019, 09:19 AM

    The Aggrenox Capsules, 25 mg/200 mg market achieved annual sales of approximately $165.6 million

    Read More
  • Glenmark Pharmaceuticals’ arm receives ANDA approval for Solifenacin Succinate Tablets
    21st May 2019, 09:26 AM

    The company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio

    Read More
  • Glenmark’s arm gets final USFDA’s approval for Esomeprazole Magnesium Delayed-Release Capsules
    14th May 2019, 10:10 AM

    The Nexium Delayed- Release Capsules, 20 mg and 40 mg market achieved annual sales of approximately $395.1 million

    Read More
  • Glenmark reports positive results from Phase 3 study of Ryaltris
    9th May 2019, 09:06 AM

    The study in patients aged 6 to under 12 years met its primary endpoint

    Read More
  • Glenmark Pharma expecting 12 to 14% growth in its India revenues during FY20
    3rd May 2019, 10:36 AM

    During the first nine months of the FY19, the company reported Rs 2109 crore revenues

    Read More
  • Glenmark pharmaceuticals’ arm enters into co-promotion agreement with Otonomy
    3rd May 2019, 09:50 AM

    This agreement provides Glenmark Therapeutics with an exclusive right to promote OTIPRIO for the treatment of acute otitis externa

    Read More
  • Glenmark launches novel, globally-researched anti-diabetes drug Remogliflozin in India
    30th Apr 2019, 09:33 AM

    The drug is indicated in the treatment of type-2 diabetes mellitus in adults

    Read More
  • Glenmark gets nod from Russian Ministry of Healthcare for Momate Rhino nasal spray
    25th Apr 2019, 09:04 AM

    The Momate Rhino metered nasal spray is used for the treatment of seasonal and perennial allergic rhinitis

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.